Agalsidase beta Withdrawn Phase 4 Trials for Fabry's Disease Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT00312767A Study in Patients With Fabry Disease Who Are on Chronic Hemodialysis Therapy for Treatment of End-stage Renal Insufficiency.